Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.2K citations

Veterinary Medicine, Immunology, Pharmacotherapy +12

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

Joseph Keane, Sharon K. Gershon, Robert P. Wise et al. · New England Journal of Medicine · 2001 · 3.7K citations · Full text

Medicine, Immunology, Pharmacotherapy +16

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

Stephan R. Targan, Stephen B. Hanauer, Sander J. H. van Deventer et al. · New England Journal of Medicine · 1997 · 3.2K citations · Full text

Pharmacy, Immunology, Inflammation +12

Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis

Peter E. Lipsky, Désirée van der Heijde, E. William St. Clair et al. · New England Journal of Medicine · 2000 · 3K citations · Full text

Medicine, Immunology, Pharmacotherapy +14

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

Ravinder N. Maini, E. William St. Clair, Ferdinand C. Breedveld et al. · The Lancet · 1999 · 2.4K citations

Medicine, Pharmacology, Pharmacotherapy +17